Electro-Capacitive Cancer Therapy (ECCT), a non-invasive electric-field–based treatment used alongside standard therapies, showed meaningful benefits in a case series of six patients with advanced lung adenocarcinoma, including both EGFR-mutant and EGFR-wild-type profiles. Across the cohort, five patients experienced partial tumor response and one achieved stable disease, with imaging demonstrating notable tumor regression and improved clinical condition. ECCT was well tolerated with no severe adverse events, even when combined with chemotherapy, immunotherapy, radiotherapy, or targeted EGFR-TKI treatments. These results indicate that ECCT may enhance the effectiveness of conventional treatments across molecular subtypes while maintaining a favorable safety profile. Conclusion: This case series suggests that ECCT is a safe and effective adjunctive therapy for stage IV lung adenocarcinoma, significantly enhancing the efficacy of standard treatments across different molecular subtypes.

国際抗老化再生医療学会雑誌 第 6 巻（20−33）2024
By Shinichiro Akiyama, MD, PhD, FACP
Cancer gene; Immunotherapy Expert
Clinical Oncology, McGill University, CANADA
Faculty of Science and Technology, Keio University, JAPAN

Mechanism of Action

Electro Capacitive Cancer Therapy (ECCT) employs low-voltage, medium-frequency electric fields to disrupt mitotic progression by inducing microtubule depolymerization, ultimately triggering apoptosis in cancer cells while sparing normal tissues. By interfering with the electrostatic forces that stabilize spindle formation during cell division, ECCT selectively targets proliferating malignant cells without the systemic toxicity associated with conventional therapies such as chemotherapy and radiotherapy.

Preclinical Evidence

In vitro and in vivo studies have demonstrated ECCT’s efficacy in suppressing tumor growth, with research indicating a 28–39% reduction in cancer cell proliferation and significant tumor shrinkage in murine models. Further investigations have revealed ECCT-mediated downregulation of IL-18 and CCL-2, key inflammatory cytokines implicated in tumor progression, as well as p53-independent p21 pathway activation leading to apoptosis in osteosarcoma cells. These findings highlight ECCT’s potential as a targeted, non-cytotoxic oncologic intervention.

Clinical Evidence

ECCT has shown promising outcomes in multiple malignancies, including glioblastoma multiforme (GBM), breast cancer, lung cancer, and lymphoma, as evidenced by a retrospective analysis of 5,195 patients. A Kaplan-Meier survival analysis in GBM patients revealed a median overall survival (OS) of 28.9 months for ECCT-treated individuals versus 15.6 months for those receiving Temozolomide (TMZ) alone, suggesting superior efficacy with ECCT. Furthermore, ECCT’s safety profile was highly favorable, with no high-grade systemic toxicity reported and only mild, localized discomfort in select cases.

Tumor Response Classification

Electrical Capacitance Volume Tomography (ECVT) has enabled the stratification of tumor responses into five categories, with soft, medium-to-high-grade tumors exhibiting the most favorable responses to ECCT, while highly aggressive phenotypes necessitate extended monitoring due to rapid metastatic potential. These findings suggest that ECCT may be particularly effective in certain tumor subtypes, warranting further investigation into
patient selection criteria.

Future Directions

As a non-invasive, well-tolerated therapeutic modality, ECCT holds significant potential for patients with advanced, refractory, or chemotherapy-intolerant malignancies. Future research will focus on optimizing treatment parameters, investigating synergies with immune checkpoint inhibitors, and conducting large-scale, randomized clinical trials to establish ECCT as a paradigm-shifting oncologic intervention with broad clinical applicability.
If validated through further studies, ECCT could redefine the landscape of cancer treatment by offering a novel, mechanistically distinct alternative to conventional cytotoxic therapies.

The research highlights the significance of monitoring frequency in ECCT’s impact on the lifespan of patients with breast, brain, and lung cancers. It suggests that each extra monitoring session can potentially reduce the risk of death by 10-20%. In essence, this study underscores ECCT’s potential effectiveness as a treatment option for cancer patients.

The research highlights the significance of monitoring frequency in ECCT’s impact on the lifespan of patients with breast, brain, and lung cancers. It suggests that each extra monitoring session can potentially reduce the risk of death by 10-20%. In essence, this study underscores ECCT’s potential effectiveness as a treatment option for cancer patients.

Researchers have uncovered the effectiveness of low-intensity, intermediate-frequency alternating electric fields in halting the growth of cancer cells. This innovative method has undergone rigorous testing, proving successful in lab settings (in vitro), animal trials (in vivo), and even in a select group of human patients battling recurrent glioblastoma, a formidable brain tumor. The outcomes are nothing short of remarkable, revealing a substantial increase in the time to disease progression and overall survival rates, all while maintaining minimal side effects. This groundbreaking discovery not only offers hope for those facing challenging forms of cancer but also signifies a promising stride toward more effective and less intrusive treatment options.

Advancements in alternating electric fields can significantly improve the survival rates of patients with metastatic non-small cell lung cancer (mNSCLC) who have not responded to platinum-based chemotherapy. This study shows that combining alternating electric field therapy with standard-of-care treatments can lead to better outcomes compared to standard-of-care treatments alone.

Electric Fields therapy has demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) when applied with adjuvant CAS 85622-93-1 compared to CAS 85622-93-1 alone in newly diagnosed glioblastoma (ndGBM). Electric Fields therapy delivers electric fields, through scalp-placed arrays, that disrupt cellular processes critical for cancer cell viability, is CE marked for WHO grade 4 glioma, and is a recommended treatment regimen for ndGBM. Electric Fields  therapy was administered to >25,000 patients, showing no systemic toxicities and mild to moderate skin reactions being the main therapy-related adverse event. Here, the report survival and safety data from the TIGER study, the largest prospective study investigating real-world use of TTFields therapy during routine clinical care in patients with ndGBM in Germany. 

Key Findings:

1. Patient Demographics and Study Design:
   • This human pilot study involved 41 patients with late-stage metastatic cancer, all with solid tumors that were unresponsive to conventional therapies such as chemotherapy and radiotherapy. These patients were considered for Positive Electrostatic Charge Therapy (PECT) as a last resort.
2. Tumor Response:
   • Significant Tumor Reduction: Over 80% of the patients exhibited a measurable reduction in tumor size, with some tumors shrinking by more than 50%. This significant reduction occurred without disease progression during the treatment period.
   • Stabilization of Disease: For patients who did not experience significant shrinkage, the disease was stabilized, with no further tumor growth observed.
3. Symptom Relief and Quality of Life:
   • Improvement in Symptoms: Patients reported relief from various cancer-related symptoms, such as pain and fatigue, leading to an overall improvement in quality of life. Some patients also experienced improved mobility and daily functioning.
4. Mechanism of Action:
   • The therapy is believed to work by disrupting cancer cell metabolism and inducing apoptosis through the modulation of the KRAS signaling pathway and increasing the Bax/Bcl2 ratio, favoring cell death.
   • No Damage to Normal Tissues: The treatment did not result in adverse effects on surrounding normal tissues, avoiding common side effects like skin burns or inflammation.
5. Safety Profile:
   • No Major Adverse Events: The treatment was well-tolerated by all patients, with no reports of severe side effects commonly associated with traditional cancer therapies. The absence of side effects like nausea, vomiting, or hair loss highlights the therapy’s safety.

Clinical Impact:

1. Potential as a Last-Resort Therapy:
   • For patients with late-stage metastatic cancer who have no other treatment options, PECT offers a potentially effective and safe alternative, extending life and improving quality of life.
2. Non-Invasive and Safe Alternative:
   • The non-invasive nature of PECT, coupled with its minimal side effects, positions it as a safer alternative to more toxic treatments like chemotherapy and radiotherapy.
   • This could be especially beneficial for patients who are not candidates for aggressive treatments.
3. Foundation for Larger Clinical Trials:
   • This pilot study provides a strong basis for larger, more comprehensive clinical trials. If similar results are replicated in larger populations, PECT could gain regulatory approval and become a standard treatment option for advanced cancers.
4. Broad Application Potential:
   • While this study focused on late-stage metastatic cancers, the underlying mechanisms suggest that PECT could be applicable to a variety of cancer types, potentially expanding its use across different patient groups.

Key Findings:

Electric field therapy represents a groundbreaking advancement in cancer treatment, offering hope to patients with advanced-stage cancers. This non-invasive approach uses positively charged patches applied near tumors to selectively target cancer cells while sparing healthy tissues. By exploiting the unique electrical properties of cancer cells, such as their abnormal surface charges and membrane structures, this therapy disrupts their function and signals, ultimately leading to self-destruction without harming surrounding healthy cells. Clinical trials have shown promising results: patients treated with electric field therapy experienced up to 70% tumor shrinkage in several cases, with complete remission observed in approximately 30% of advanced breast cancer and liver metastasis patients. These outcomes far exceeded those achieved with conventional therapies like chemotherapy and radiation.
​
Beyond tumor reduction, electric field therapy has improved patients’ overall well-being. In clinical studies, 80% of patients reported a reduction in cancer-related symptoms such as pain and swelling, while regaining strength to pursue additional treatments like surgery. The absence of systemic side effects, such as those commonly associated with chemotherapy (e.g., hair loss and immune suppression), underscores this therapy’s safety and tolerability. Patients experienced no adverse impacts on surrounding tissues, as confirmed by imaging and biopsy data. By combining cutting-edge science with a patient-focused approach, electric field therapy has the potential to redefine oncology, offering an effective and humane treatment option for even the most challenging cancer cases.

Key Findings:

​In a recent study published in Cell Medicine, researchers explored the potential of combining electric field therapy with the immunotherapy drug pembrolizumab to improve treatment outcomes for patients with glioblastoma—an aggressive and treatment-resistant form of brain cancer. The study found that patients who received both electric field therapy and pembrolizumab experienced a significantly longer progression-free survival (PFS) compared to those treated with immunotherapy alone, all while maintaining manageable safety profiles. On a biological level, the electric field appeared to enhance immune system activity by boosting antigen presentation and promoting T-cell infiltration into tumors. This synergistic effect with pembrolizumab suggests that electric field therapy may help overcome immune resistance in glioblastoma, marking a promising advancement in the development of more effective treatment strategies.